2000/09-2005/07，天津医科大学，医学检验学系，医学学士

2005/09-2008/07，北京大学基础医学院，病原生物学系，医学硕士

2012/09-2015/07，北京大学基础医学院，病原生物学系，医学博士

2008/09-2010/04，美国田纳西大学医学院，分子科学系，访问学者

2010/05-2011/06，北京科兴生物制品有限公司，研发中心，研发工程师

2011/07-2012/01，南开大学生命科学学院，微生物学系，研究助理

2015/08-2018/12，北京大学基础医学院，病原生物学系，讲师

2019/01-至今，北京大学基础医学院，病原生物学系，副研究员，博士生导师

中国研究型医院学会病毒肿瘤学专业委员会委员

中华预防医学会促进消除病毒性肝炎工作委员会委员

中华医学会医学病毒学分会青年委员会委员及临床病毒学组委员

中华医学会肝病学分会青年委员会委员及肝炎学组、肝癌学组和肝病基础医学与实验诊断协作组委员

中华医学科学技术二等奖

天津市科学技术进步奖

河北省科学技术进步奖

黑龙江省医药卫生科学技术二等奖

北京大学医学部教学优秀奖

北京大学基础医学院青年教师奖励基金

北京大学基础医学院优秀SCI论文奖和SCI论文引用奖

1.  乙型肝炎病毒感染的诊疗及与宿主因子的相互作用

2.  病毒感染相关肿瘤的发生机制及靶向治疗

1.  国家自然科学基金面上项目，2024.01-2027.12，负责人

2.  国家自然科学基金面上项目，2022.01-2025.12，负责人

3.  北京大学人才专项基金，2021.01-2022.12，负责人

4.  国家自然科学基金面上项目，2020.01-2023.12，负责人

5.  JW后勤部JM融合重点项目，2019.01-2022.12，子课题负责人

6.  北京市自然科学基金面上项目，2018.01-2020.12，负责人

7.  国家“传染病防治”科技重大专项，2017.01-2020.12，任务负责人（两项）

8.  国家自然科学基金面上项目，2017.01-2020.12，负责人

1.  Zheng H^#, Liu M^#, Shi S^#, Huang H, Yang X, Luo Z, Song Y, Xu Q, Li T, Xue L, Lu F, Wang J*. MAP4K4 and WT1 mediate SOX6-induced cellular senescence by synergistically activating the ATF2–TGFb2–Smad2/3 signaling pathway in cervical cancer. Molecular Oncology. 2024; 18(5):1327-1346.

2.  Liu M^#, Song Y^#, Li Y, Yang X, Zhuang H, Li J*, Wang J*. C2729T mutation associated with HBV mother-to-child transmission reduces HBV production via suppressing LHBs expression. Virulence. 2023; 14(1):2189676.

3.  Song Y, Lu Y, Li Y, Liu M, Zhuang H, Li J*, Wang J*. HBx 128-133 deletion affecting HBV mother-to-child transmission weakens HBV replication via reducing HBx level and CP/ENII transcriptional activity. Viruses. 2022; 14(9):1887.

4.  Huang H^#, Han Q^#, Zheng H, Liu M, Shi S, Zhang T, Yang X, Li Z, Xu Q, Guo H*, Lu F, Wang J*. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death & Disease. 2022; 13(1):13.

5.  Yu G, Chen R, Zheng S, Liu Y, Zou J, Gu Z, Jiang B, Gao Q, Dai L*, Peng J*, Wang J*, Lu F*. A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerging Microbes & Infections. 2022; 11(1):775-785.

6.  Li Y, Xiao Y, Li L, Song Y, Zhai X, Liu J, Duan Z, Yan L, Ding F, Liu J, Zhu L, Jiang J, Zou H, Li L, Liang C, Wang J*, Li J*. The dynamic changes of HBV quasispecies diversity in infancy after immunoprophylaxis failure: a prospective cohort study. Virology Journal. 2021; 18:236.

7.  Lu Y^#, Song Y^#, Zhai X, Zhu F, Liu J, Chang Z, Li Y, Xiao Y, Li L, Liu M, Liu J, Duan Z, Zou H, Zhuang H, Wang J*, Li J*. Maternal Hepatitis B e Antigen can be an Indicator for Antiviral Prophylaxis of Perinatal Transmission of Hepatitis B Virus. Emerging Microbes & Infections. 2021; 10(1):555-564.

8.  Xiao Y, Sun K, Duan Z, Liu Z, Li Y, Yan L, Song Y, Zou H, Liu J, Zhuang H*, Wang J*, Li J*. Quasispecies characteristic in “a” determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case-control study. Gut. 2020; 69(5):933-941.

9.  Li Y^#, Liu Z^#, Song Y, Xiao Y, Jiang J, Li L, Zhai X, Liu J, Duan Z, Ding F, Liu J, Zhuang H, Zhu L, Jiang J, Zou H, Wang J*, Li J*. Reduction of the occurrence of occult HBV infection in infants by increasing the dose of hepatitis B vaccine: A large prospective cohort study. Emerging Microbes & Infections. 2020; 9(1):1881-1891.

10. Shi S, Liu M, Xi J, Liu H, Guan G, Shen C, Guo Z, Zhang T, Xu Q, Kudereti D, Chen X, Wang J*, Lu F*. Sex-determining region Y box 4 (SOX4) suppresses hepatitis B virus replication by inhibiting hepatocyte nuclear factor 4α expression. Antiviral Research. 2020; 176: 104745.

11.Chen R, Huang H, Liu H, Xi J, Ning J, Zeng W, Shen C, Zhang T, Yu G, Xu Q, Chen X, Wang J*, Lu F*. Friend or Foe? Evidences Indicate Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein. Small. 2019; 15(38): e1902686.

12. Wang J, Jia J, Chen R, Ding S, Xu Q, Zhang T, Chen X, Liu S*, Lu F*. RFX1 participates in doxorubicin-induced hepatitis B virus reactivation. Cancer Medicine. 2018; 7(5):2021-2033.

13. Wang J^#, Chen X^#, Wu Y^#, Cao Z, Wang L, Huang H, Chen X*, Lu F*. Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion. Hepatology Communications. 2018; 2(10):1168-1171.

14. Wang J, Sheng Q, Ding Y, Chen R, Sun X, Chen X, Dou X*, Lu F*. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. Journal of Hepatology. 2018; 68:847-849.

15. Huang H^#, Wang J^#, Li W, Chen R, Chen X, Zhang F*, Xu D*, Lu F*. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. Journal of Clinical Virology. 2018; 99-100:71-78.

16. Wang J^#, Chen R^#, Zhang R^#, Ding S, Zhang T, Yuan Q, Guan G, Chen X, Zhang T, Zhuang H, Nunes F, Block T, Liu S, Duan Z, Xia N*, Xu Z*, Lu F*. The gRNA-miRNA-gRNA ternary cassette combining CRISPR/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication. Theranostics. 2017; 7(12):3090-3105.

17. Wang J^#, Shen T^#, Huang X^#, Kumar GR^#, Chen X, Zeng Z, Zhang R, Chen R, Li T, Zhang T, Yuan Q, Li PC, Huang Q, Colonno R, Jia J, Hou J, McCrae MA, Gao Z*, Ren H*, Xia N*, Zhuang H, Lu F*. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology. 2016; 65(4):700-710.

18. Wang J, Ding S, Duan Z, Xie Q, Zhang T, Zhang X, Wang Y, Chen X*, Zhuang H, Lu F*. The role of p14ARF-HDM2-p53 in SOX6-mediated tumor suppression. Oncogene. 2016; 35(13):1692-1702.

19. Wang J, Xu ZW, Liu S, Zhang R, Ding S, Xie X, Chen X, Zhuang H, Lu F*. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World Journal of Gastroenterology. 2015; 21(32): 9554-9565.

20. Liu B, Li NL, Wang J, Shi PY, Wang T, Miller MA, Li K*. Overlapping and district molecular determinants dictating the antiviral activities of TRIM56 against flaviviruses and coronavirus. Journal of Virology. 2014; 88(23):13821-13835.

21. Shen Y, Li NL, Wang J, Liu B, Lester S, Li K*. TRIM56 is an essential component of the TLR3 antiviral signaling pathway. Journal of Biological Chemistry. 2012; 287(43):36404-36413.

22. Wang J, Liu B, Wang N, Lee YM, Liu C, Li K*. TRIM 56 is a virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection. Journal of Virology. 2011; 85(8):3733-3745.